Pharmaceuticals
ERT and Bioclinica become Clario, The Leading Technology Solutions Company for Clinical Trial Innovation and Evidence
PHILADELPHIA, Nov. 3, 2021 /PRNewswire/ -- ERT, the global clinical endpoint technology leader, today announced that following its early Q2 merger with Bioclinica, a technological and scientific leader in medical imaging, the combined company is renamed Clario. Clario is a technology company tha...
2021-11-03 21:33
4065
Standigm Files PCT Patent Application of AI-driven Repurposed Drugs for Primary Mitochondrial Disease
SEOUL, South Korea, Nov. 3, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had filed PCT ("Patent Cooperation Treaty") patent application covering AI-driven repurposed drugs for primary m...
2021-11-03 21:00
2252
I-Mab Announces Upcoming Participation at November Conferences
SHANGHAI and GAITHERSBURG, Md., Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in Novemb...
2021-11-03 20:00
1953
BioKangtai's adenovirus vector COVID-19 vaccine obtained EUA in Indonesia
SHENZHEN, China, Nov. 3, 2021 /PRNewswire/ -- As reported by Indonesian National Agency of Drug and Food Control (BPOM), BPOM grants the Emergency Use Authorization (EUA) for COVID-19 Vaccine (ChAdOx1-S[recombinant])/KconecaVac manufactured by Shenzhen Kangtai Biological Products Co., Ltd. It is ...
2021-11-03 19:02
2266
Tabernacle Health Group Launches Revolutionary Immunity Booster!
SINGAPORE, Nov. 3, 2021 /PRNewswire/ -- As a result of the pandemic, boosting one's immune system has never been more crucial. Consisting of numerous chemicals, cells, proteins, and tissues that work together, the immune system is responsible for creating, storing, and distributing white blood ce...
2021-11-03 10:00
2877
Kintor Pharma Doses First Patient in Clinical Trial of ALK-1 in Combination with KN046 In Advanced or Refractory Solid Tumors
SUZHOU, China, Nov. 3, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has enrolled and dosed its first patient with advanced...
2021-11-03 08:32
2726
Daewoong's "Leaps and Bounds" Q3 Performance, Exceeds KRW 20B in Operating Income for Three Consecutive Quarters
* Advancement of Nabota and prescriptions... KRW 290.6B sales and KRW 22.7B operating income * Expanding growth momentum with the release of Fexuprazan in Korea and Nabota inEurope next year SEOUL, South Korea, Nov. 2, 2021 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) (CEOSengho Jeon) a...
2021-11-02 21:00
2216
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer
HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that AK112 (PD-1/VEGF bi-specific antibody), the novel immuno-oncology drug independently developed by the Company, obtained approval from the Center for Drug Evaluation (CDE) of the National Medical Products Ad...
2021-11-02 11:53
2434
Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma
SHANGHAI and HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-11-02 08:30
4440
111 to Announce Third Quarter 2021 Unaudited Financial Results on November 19, 2021 - Conference Call to Follow
SHANGHAI, Oct. 28, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...
2021-11-02 04:57
3835
Qilian International Holding Group Limited Donates Pharmaceutical Products Gan Di Xin® Worth RMB500,000 and Other Materials to Help Fight Local COVID-19 Epidemic
JIUQUAN, China, Nov. 1, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that recently, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), the Comp...
2021-11-01 20:00
2157
I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments
SHANGHAI and GAITHERSBURG, Md., Nov. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced the appointment ofJohn Long as the Company's Chief Finan...
2021-11-01 20:00
2180
Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study
* U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study * The PREVAIL Study remains on target to initiate by end of 2021 and is expected to read out topline data by end of 2022 ADELAIDE, A...
2021-11-01 18:00
3129
Farrer Park Hospital Introduced Actinium-225 PSMA Nuclear Therapy for Advanced Prostate Cancer
Earlier trials using Actinium-225 PSMA showed an improved biochemical response and better cancer-killing effects as Actinium-225 PSMA uses a much more potent radioactive ligand. SINGAPORE, Nov. 1, 2021 /PRNewswire/ -- Prostate cancer is the 3rd most common cancer among Singaporean men. Every day...
2021-11-01 08:15
2622
Everest Medicines Announces Share Repurchase Transaction Details
SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that it ...
2021-11-01 08:00
3172
Operating Income of Yiling Pharmaceutical in First 3 Quarters Reaches CNY 8.112 Billion, Up 25.81%
SHIJIAZHUANG, China, Oct. 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical released the three-quarter report on the evening ofOctober 28. In the first three quarters, the operating income of the company reachedCNY 8.112 billion, up 25.81% year on year; the net profit attributable to shareholders of...
2021-10-29 17:17
1961
3M Health Care and Thermo Fisher Scientific Collaborate to Increase Process Efficiency and Scalability in Commercial Therapeutic Manufacturing
- Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers - Solution enables manufacturers to optimize manufacturing capacity, quality, efficiency and scalability ST. PAUL, Minn., Oct. 29, 2021 /PRNewswire/ -- 3M Separation and Purification ...
2021-10-29 15:45
2291
IMPACT Therapeutics Announced ATR Inhibitor IMP9064 IND Clearance by FDA
SHANGHAI, Oct. 29, 2021 /PRNewswire/ -- IMPACT Therapeutics announced that its ATR inhibitor IMP9064 has received the IND clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, which will begin soon in the U.S. This will be the first in human study for the A...
2021-10-29 14:12
2209
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC
SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 inChina (ENREACH-LUNG-02) recently completed the first drug administration. ENREACH-LUNG-02 is a multi-center, open-label, randomized...
2021-10-29 09:36
3068
Hanmi Science Consortium Drives Ambitious Project for Worldwide Vaccine Equity
SEOUL, South Korea, Oct. 29, 2021 /PRNewswire/ -- Hanmi Science doesn't just want the world to know they are committed to vaccine equity, they want to prove it. Mr. Lim, CEO of Hanmi Science, echoes the concerns of Mr.Bill Gates, co-founder of the Bill & Melinda Gates Foundation. As Mr. Gates sta...
2021-10-29 09:27
3202
Week's Top Stories
Most Reposted
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
[Picked up by 317 media titles]
2026-07-24 12:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 297 media titles]
2026-07-20 15:00
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
[Picked up by 295 media titles]
2026-07-23 16:00
Phuket Marriott Resort & Spa, Merlin Beach Elevates Guest Experience with New Dining and Family Facilities
[Picked up by 290 media titles]
2026-07-24 18:32
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
[Picked up by 288 media titles]
2026-07-24 16:25
Most Read
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
2026-07-20 15:00
13710